Advancing Fibrosis Therapy
We are committed to developing first-in-class therapies targeting the root causes of tissue fibrosis, offering new hope and improved quality of life for patients with fibrotic diseases worldwide.
The company
3D-FibroScreen is a spin-off from the Université libre de Bruxelles (ULB), founded in 2025.
The company pioneers advanced 3D cell culture models that replicate native tissue environments, enabling more effective drug discovery for fibrosis.
By harnessing these innovative phenotypic platforms, 3D-FibroScreen drives rapid identification and validation of novel anti-fibrotic therapies and aims to transform
research breakthroughs into impactful treatments.
THE CO-FOUNDERS
Alexander Goemans, Chairman
Alexander Goemans is a life sciences executive with 10+ years’ experience scaling startups from R&D to clinical stages and regulatory approval. Ex-McKinsey & Gimv, he raised €300M+, closed deals with GSK, Grandpharma, UCB & Mars, and holds degrees in finance, drug development & molecular pathology.
Charlene Jouy, Scientific Manager
Charlène Jouy holds a PhD in Biology and an Executive MBA, with a mission to drive innovation beyond the lab by accelerating the translation of scientific insights into business opportunities. Her career spans advanced biomedical research and the development of a cutting-edge pharmaceutical screening platform, positioning her at the intersection of science and strategy
Nicolas Baeyens, Scientific Consultant
Nicolas Baeyens is a leading researcher and academic with expertise in mechanobiology. Throughout his career, he has made substantial contributions to elucidating the influence of mechanical forces on different clinical disorders. His work has been published in high-impact scientific journals